TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-17

Archived explainer. For the current picture see today's LYCA page.

Why Is LYCIA THERAPEUTICS I (LYCA) Stock Up Today?

By the Top Tier Newswire AI Desk · November 17, 2026 at 9:45 AM ET · reviewed against 10 wire stories

LYCIA THERAPEUTICS I (LYCA) is up +6.12% in the latest session. Our newswire has captured 10 stories on LYCA across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Lycia Therapeutics (LYCA) shares rose 6.12% to $30.36 as a wave of new analyst coverage initiated positive ratings on the stock. The primary driver was the simultaneous launch of coverage by multiple investment banks, which signaled strong institutional interest in the company’s food allergy franchise.

What Happened

Jefferies initiated coverage of Lycia Therapeutics with an Outperform rating and a price target of $50. Guggenheim also started coverage with a Buy rating, citing the potential of the food allergy market. TD Cowen initiated the stock with a Buy rating, while Evercore ISI assigned an Outperform rating. LifeSci Capital also initiated coverage with an Outperform rating. This cluster of positive initiations represents a significant shift in analyst attention for the company.

What The Data Shows

The stock opened at $28.62 and reached a session high of $31.29 at 9:30 AM ET before settling at $29.75. Volume so far is reported at 0.0M shares. The company has a market capitalization of $1.8B and trades within a 52-week range of $22.19 to $36.49. Over the last 8 sessions, the stock moved down 0.7%, declining from $28.80 to $28.61. However, the stock printed three fresh 52-week highs on 2026-11-17. Recent insider activity shows Venrock Healthcare Capital Partners Iii, L.P. bought shares on 2026-11-02, 2026-10-28, and 2026-10-23. In the last 90 days, there were 3 buys totaling $38.5M and 0 sells, with the most recent filing on 2026-11-04.

What To Watch

Lycia Therapeutics is scheduled to present at the 2026 Jefferies Global Healthcare Conference. Investors may monitor how the new price targets from Jefferies, Guggenheim, and TD Cowen are received in the coming sessions.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

LYCA by the numbers

Last: $30.36Session: +6.12%7 sessions: +1.38%Coverage: 10 stories / 3 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $1.8B52w: $22.19 to $36.49
LYCA · Nov 17 session (5-min) · +7.69% vs prior close · updated 8:46 PM ET
$28.43$30.15$31.87prev close $28.61$30.819:30 AM11:40 AM1:50 PM4:00 PM6:10 PM9:30 AM · $31.299:35 AM · $30.239:40 AM · $29.759:45 AM · $30.579:50 AM · $30.259:55 AM · $30.3010:05 AM · $30.4310:10 AM · $30.3910:15 AM · $29.9410:20 AM · $29.8810:25 AM · $30.0110:35 AM · $30.4510:40 AM · $30.3610:45 AM · $30.7010:50 AM · $30.3410:55 AM · $30.2011:00 AM · $30.3411:05 AM · $29.9811:10 AM · $29.5911:15 AM · $30.1611:20 AM · $29.8111:25 AM · $30.3711:30 AM · $30.3211:35 AM · $30.3711:40 AM · $30.4011:45 AM · $30.5611:50 AM · $30.6011:55 AM · $30.6812:00 PM · $30.8712:05 PM · $30.9012:10 PM · $30.9512:15 PM · $31.2312:20 PM · $31.2412:25 PM · $31.1412:30 PM · $31.3112:35 PM · $31.3012:40 PM · $31.3312:45 PM · $31.2712:50 PM · $31.2912:55 PM · $31.281:05 PM · $31.251:10 PM · $31.331:15 PM · $31.381:20 PM · $31.381:25 PM · $31.341:30 PM · $31.151:35 PM · $31.051:40 PM · $31.011:45 PM · $31.132:00 PM · $31.082:05 PM · $31.282:10 PM · $31.292:15 PM · $31.362:25 PM · $31.272:30 PM · $31.572:35 PM · $31.562:40 PM · $31.552:45 PM · $31.552:50 PM · $31.682:55 PM · $31.143:00 PM · $31.273:05 PM · $31.153:10 PM · $31.133:15 PM · $31.133:20 PM · $31.203:25 PM · $30.993:30 PM · $30.953:35 PM · $31.143:40 PM · $31.143:45 PM · $31.103:50 PM · $30.803:55 PM · $30.784:00 PM · $30.926:10 PM · $30.81
AI sentiment, last 36h · averaged over 10 stories · 63/100 bullish
AI sentiment 63/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishThe Fly · sentiment 63 · Lycia Therapeutics initiated with an Outperform at Evercore ISIThe Fly · 63Lycia Therapeutics initiated with an Outperform at Evercore ISIThe Fly · sentiment 63 · Lycia Therapeutics initiated with a Buy at JefferiesThe Fly · 63Lycia Therapeutics initiated with a Buy at JefferiesThe Fly · sentiment 63 · Lycia Therapeutics initiated with a Buy at TD CowenThe Fly · 63Lycia Therapeutics initiated with a Buy at TD CowenInvesting.com Analyst Ratings · sentiment 63 · Guggenheim initiates Lycia Therapeutics stock with buy ratingInvesting.com Analyst Ratings · 63Guggenheim initiates Lycia Therapeutics stock with buy ratingThe Fly · sentiment 63 · Lycia Therapeutics initiated with a Buy at GuggenheimThe Fly · 63Lycia Therapeutics initiated with a Buy at GuggenheimThe Fly · sentiment 64 · Guggenheim starts Lycia Therapeutics with a Buy on food allergy market potentialThe Fly · 64Guggenheim starts Lycia Therapeutics with a Buy on food allergy market potentialThe Fly · sentiment 63 · Lycia Therapeutics initiated with an Outperform at LifeSci CapitalThe Fly · 63Lycia Therapeutics initiated with an Outperform at LifeSci CapitalGuruFocus · sentiment 61 · LYCA Initiated by Jefferies -- Price Target Announced at $50GuruFocus · 61LYCA Initiated by Jefferies -- Price Target Announced at $50
3d agoGuruFocusBULLISH 61Analyst

LYCA Initiated by Jefferies -- Price Target Announced at $50

3d agoThe FlyBULLISH 63Analyst

Lycia Therapeutics initiated with an Outperform at LifeSci Capital

3d agoThe FlyBULLISH 64Analyst

Guggenheim starts Lycia Therapeutics with a Buy on food allergy market potential

3d agoThe FlyBULLISH 63Analyst

Lycia Therapeutics initiated with a Buy at Guggenheim

3d agoInvesting.com Analyst RatingsBULLISH 63Analyst

Guggenheim initiates Lycia Therapeutics stock with buy rating

Guggenheim initiates Lycia Therapeutics stock with buy rating

3d agoThe FlyBULLISH 63Analyst

Lycia Therapeutics initiated with a Buy at TD Cowen

3d agoThe FlyBULLISH 63Analyst

Lycia Therapeutics initiated with a Buy at Jefferies

3d agoThe FlyBULLISH 63Analyst

Lycia Therapeutics initiated with an Outperform at Evercore ISI

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on LYCA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier LYCA move explainers: 2026-11-18 · 2026-11-17